Valuation: Roche Holding AG

Market Cap 286B 353B 306B 262B 496B 33,556B 502B 3,367B 1,316B 16,774B 1,325B 1,296B 55,580B P/E 2026 *
19.9x
P/E 2027 * 17.7x
Enterprise Value 296B 366B 318B 272B 515B 34,818B 521B 3,494B 1,366B 17,405B 1,375B 1,344B 57,671B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.42x
Free-Float
88.78%
Yield 2026 *
2.79%
Yield 2027 * 2.86%
1 day+1.08%
1 week-1.76%
Current month+0.57%
1 month+5.46%
3 months+8.75%
6 months-1.27%
Current year+6.96%
1 week 381.8
Extreme 381.8
394.8
1 month 357.4
Extreme 357.4
401.6
Current year 338
Extreme 338
418
1 year 270.2
Extreme 270.2
418
3 years 270.2
Extreme 270.2
418
5 years 270.2
Extreme 270.2
418
10 years 181.6
Extreme 181.6
418
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-1.76% - - 353B
-0.51%-8.60%+45.08%+148.21% 995B
+0.20%-4.42%+49.05%+50.81% 614B
-0.53%-7.37%+23.64%+65.03% 431B
-0.03%-3.85%+30.66%+38.83% 293B
-1.29%-11.44%+3.66%+6.84% 245B
-4.16%-12.48%-3.29%-45.79% 210B
+2.94%-0.78%+29.17%+60.32% 210B
+3.13%+0.69%+18.11%+71.90% 168B
+1.52%+0.63%+7.99%-27.44% 145B
Average +0.15%-4.55%+22.68%+40.97% 367.81B
Weighted average by Cap. +0.18%-5.90%+31.62%+69.76%

Financials

2026 *2027 *
Net sales 62.64B 77.38B 67.19B 57.55B 109B 7,360B 110B 739B 289B 3,679B 291B 284B 12,191B 65.47B 80.87B 70.22B 60.15B 114B 7,693B 115B 772B 302B 3,845B 304B 297B 12,742B
Net income 14.51B 17.92B 15.56B 13.33B 25.2B 1,704B 25.48B 171B 66.86B 852B 67.29B 65.81B 2,823B 16.33B 20.17B 17.52B 15B 28.38B 1,919B 28.69B 193B 75.27B 959B 75.76B 74.1B 3,179B
Net Debt 10.74B 13.27B 11.52B 9.87B 18.67B 1,262B 18.87B 127B 49.52B 631B 49.84B 48.75B 2,091B 3.96B 4.9B 4.25B 3.64B 6.89B 466B 6.96B 46.72B 18.26B 233B 18.38B 17.98B 771B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-08-05 390.20 +0.62% 155
26-08-04 €387.80 -0.67% 52
26-08-03 €390.40 +0.62% 209
26-07-31 €388.00 +0.26% 38
26-07-30 €387.00 -2.57% 164
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
357.70CHF
Average target price
363.92CHF
Spread / Average Target
+1.74%

Quarterly revenue - Rate of surprise